✉ Email this page to a colleague
« Back to Dashboard
BKM120 is an investigational drug.
There have been 82 clinical trials for BKM120. The most recent clinical trial was a Phase 3 trial, which was initiated on October 3rd 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are four hundred and forty-eight US patents protecting this investigational drug and five international patents.
Recent Clinical Trials for BKM120
|Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors||Adlai Nortye Biopharma Co., Ltd.||Phase 1|
|Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Novartis||Phase 1|
|Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Emory University||Phase 1|
Top disease conditions for BKM120
Top clinical trial sponsors for BKM120
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|BKM120||See Plans and Pricing||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||See Plans and Pricing|
|BKM120||See Plans and Pricing||Substituted thiohydantoin derivatives as androgen receptor antagonists||Janssen Pharmaceutica NV (Beerse, BE)||See Plans and Pricing|
|BKM120||See Plans and Pricing||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|BKM120||See Plans and Pricing||Bicyclic fused pyrimidine compounds as TAM inhibitors||Incyte Corporation (Wilmington, DE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|BKM120||Australia||AU2015231053||2034-03-21||See Plans and Pricing|
|BKM120||Brazil||BR112016021620||2034-03-21||See Plans and Pricing|
|BKM120||Canada||CA2943339||2034-03-21||See Plans and Pricing|
|BKM120||China||CN106231900||2034-03-21||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|